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Non-Hodgkin’s lymphoma (NHL) comprises a hetero-
geneous group of cancers of the lymphoid system. The
incidence of this disease is increasing worldwide. In Brazil,
approximately 55,000 new cases are reported each year, and
over 26,000 deaths result from NHL annually. In the state of
Sao Paulo, the incidence is 12.2 cases per 100,000 inhabi-
tants.1 B-cell lymphomas are the most common forms of
NHL, and diffuse large B-cell lymphoma (DLBCL) is the
most common subtype. The International Prognostic Index
(IPI) is the primary clinical prognostic index used to classify
individuals into different subgroups according to their
DLBCL risk.
In the last decade, the overall survival (OS) of DLBCL
patients has increased dramatically as a result of the
development of cyclophosphamide/doxorubicin/vincris-
tine/prednisone (CHOP) therapy. The addition of ritux-
imab, which is a monoclonal antibody (mAb) against CD20,
to CHOP therapy results in a treatment paradigm known as
R-CHOP. Although R-CHOP is one of the most effective
treatments available, approximately 50% of DLBCL patients
are refractory to R-CHOP treatment. Rituximab is a
humanized IgG1 mAb that specifically binds to CD20, a
surface antigen present in the majority of B-NHLs.
Although the exact mechanism(s) underlying its anti-tumor
activity has not been clearly defined, rituximab has been
suggested to act via the induction of cell cycle arrest and
apoptosis, sensitization to cytotoxic drugs, complement-
dependent cytotoxicity and antibody-dependent cellular
cytotoxicity (ADCC).2 The Fc fragment of rituximab is the
major mediator of its therapeutic activity and acts by
binding to Fcc receptors (FccR) expressed by effector cells.3
Three FccR classes (I, II, III) and eight subclasses have been
described, with different haplotype distributions present in
different ethnic groups.4 Polymorphisms in FccR genes have
been associated with anti-tumor efficacy, and this hetero-
geneous family of receptors is known to play a critical role
in immunity by linking humoral responses to cellular
responses.3 FccRIIa (CD32a) and FccRIIIa (CD16) are known
to activate effector cells, whereas FccRIIb (CD32b) has been
shown to inhibit the activation of effector cells.
FCcRIIA, the most widely expressed FccR, is characterized
by a single nucleotide polymorphism (SNP) resulting in either
arginine (R) or histidine (H) at position 131 within the
membrane-proximal Ig-like domain that determines the recep-
tor’s affinity for IgG immune complexes. Consequently, the
most striking disparity between the R and H alleles of FccRIIA-
131 is a significant increase in the affinity of the H allele for
human IgG2 (and, to a lesser extent, for IgG1 and IgG3).3
Therefore, it is possible that this SNP can influence the anti-
tumor abilities of effector cells. However, conflicting results
have been reported concerning the role of this FccRIIA
polymorphism. For example, a significant correlation
between the FccRIIA 131 H/H genotype and responses to
rituximab has been identified in patients with follicular
lymphoma but does not occur in patients with chronic
lymphocytic leukemia.5,6 Regarding DLBCL, the FccRIIA 131
H/H genotype was shown to be predictive for complete
remission, but not for overall survival or progression-free
survival, in patients with B-cell NHL who had been treated
with rituximab and chemotherapy (R-CH).7 However, this
study examined a heterogeneous group of patients with
different subtypes of NHL, including indolent, aggressive
and very aggressive NHL. Other studies have found no
significant associations between FccRIIA polymorphisms
and complete remission (CR) rates in DLBCL patients.8
However, the aforementioned studies were performed in
Caucasians, and their relevance to individuals of other ethnic
backgrounds remains undetermined. Brazilians are one of
the most heterogeneous populations in the world, a
characteristic that results from five centuries of interethnic
crosses between peoples from three continents: Europeans,
Africans and Amerindians.9,10 How this large genetic
mixture affects the influence of the FccRIIA-131 polymorph-
ism in the treatment of DLBCL patients is not known. In this
study, we investigated the effects of the FccRIIA-131
polymorphism on the overall survival, disease-free survival
and overall response rate to R-CHOP treatment in a cohort of
59 Brazilian patients with DLBCL.
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After receiving written informed consent, blood was
drawn from 59 previously untreated patients with DLBC.
The protocol design was approved by the Institutional
Ethics Committee. Patients were treated with 6–8 cycles of
R-CHOP chemotherapy (rituximab 375 mg/m2 iv, cyclopho-
sphamide 750 mg/m2 iv, doxorubicin 50 mg/m2 iv,
vincristine 1.4 mg/m2 iv (max 2.0 mg) and prednisone
100 mg/day po days 1–5) every 3–4 weeks. Patients who
were seropositive for human immunodeficiency virus (HIV)
and those with severe congestive heart failure, kidney
failure or liver failure were not included in the study.
Patients with bulky disease (i.e., . 7.0 cm) were subjected to
radiotherapy (30 Gy) 28 days after the last cycle of
chemotherapy. Intrathecal chemotherapy with methotrexate
(12 mg) and dexamethasone (2 mg) was administered to
patients who exhibited a high risk of central nervous system
relapse. The median follow-up time was 19.5 months (range
21.3 to 50.1).
Complete responses to treatment were defined by the
complete lack of lymphoma-related signs and symptoms.
The criteria for partial responses to treatment (PR) were a
50% (or greater) reduction in lesion size (calculated by
finding the sum of the two major measurable perpendicular
lengths of the lesions), or the lack of increases in pre-existing
lesions, new lesions and B symptoms. Complete mass
reductions were considered to be PR when bone marrow
infiltration persisted. Responses that failed to meet the
criteria for PRs were characterized as refractory, and the
development of residual lesions of 25% or more and the
appearance of new lesions were considered to be indicative
of relapse.11
All of the patients underwent a diagnostic work-up
consisting of a tumor biopsy; medical history; biometric
tests; a complete blood count; liver and kidney evaluations;
serum lactate dehydrogenase (LDH) and ß-2 microglobulin
measurements; serum protein electrophoresis; serology for
HBV, HCV, HIV, HTLV-I/II, syphilis, and South American
trypanosomiasis; an electrocardiogram; an echocardiogram;
a chest radiography; bilateral BM biopsies; a lumbar
puncture; and neck, chest, abdomen, and pelvis computer
tomography (CT). Patients whose Waldeyer’s ring had been
involved underwent digestive endoscopies, and those
whose facial bones were involved underwent brain and
face CTs. Response evaluations were performed after the 4th
treatment cycle, the last treatment cycle, every 3 months
during the first 2 years after treatment and every 6 months
thereafter.
Blood samples were collected in EDTA-containing tubes.
DNA was extracted using standard salting out procedures
as described elsewhere.12, 13 Oligonucleotides for polymer-
ase chain reaction (PCR) amplification were chosen to
specifically amplify the FccRIIA gene and not the highly
homologous FccRIIB and FccRIIC genes. The following
oligonucleotides were synthesized by Integrated DNA
Technologies (Coralville, IA): sense: 59-GGAAAATC-
CCAGAAATTCTCGC-39 and antisense: 59-CAACAGC-
CTGACTACCTATTACGCGGG-39. PCR amplification was
performed as described previously.14
Overall survival time was defined as the time period from
the beginning of treatment until either the time of death or
the time of the last follow-up appointment. The overall
response rate was defined as the total percentage of cases
exhibiting either complete or partial responses. The disease-
free survival period was defined as the time period from the
beginning of each positive treatment response until the first
observed disease progression, relapse, death, or the last
follow-up. Data were analyzed using the Kaplan-Meier
method. GraphPad Prism (v5.0) software was used for
statistical calculations, and P values , 0.05 were considered
to be statistically significant.
The clinical characteristics of patients are summarized in
Table I. The median age of the patients was 48.6 years.
Thirty (50.8%) patients were in Ann Arbor stage III–IV and
29 patients were in stage I–II. Twenty-four (40.7%) patients
had more than 3 factors of IPI. Of the patients included in
this study, 50 (84.7%) had complete remission, 6 (10.1%) had
refractory disease and 7 (11%) relapsed. Six of the study
patients (10.1%) died prior to their follow-up
(data not shown).
Of the patients in the current study, 15 (25.4%) were
homozygous for the H allele, 27 (45.8%) for HR and 17
(28.8%) for RR. Thus, the frequency of H and R alleles in this
patient population is consistent with previous reports in the
literature.7,8
The overall response rate was not affected by the FccRIIA-
131 polymorphism (data not shown). Complete responses
were observed in 80% and 89% of patients with HH and
HR/RR genotypes, respectively (p= 0.377). Similarly,
FccRIIA polymorphisms were shown to exhibit no signifi-
cant effects on either disease-free survival or overall
survival. Overall, the mean survival time was 23.26 ¡
10.42 months for individuals carrying the HH genotype and
12.7¡ 7.42 months for individuals carrying either the HR or
the RR genotype (p= 0.98, 95% CI - 0.1194 to 8.801)
(Figure 1A). The mean disease-free survival time for
individuals with the HH and the HR/RR genotype was
20.96¡ 10.49 months and 12.03¡ 7.71 months, respectively
(p = 0.765, 95% CI - 0.2588 to 9.419) (Figure 1B).
The observed level of R-CHOP treatment response in the
current study is comparable to those published in the
literature. In addition, the lack of an association between the
FccRIIa-131 polymorphism and R-CHOP responses is in
Table I - Pretreatment characteristics of patients
Parameter Number of patients Percentage
Sex
Male 30.0 50.8
Female 29.0 49.2
Age (years)
# 60 44.0 74.6
. 60 15.0 25.4
Clinical Staging
I/ II 29.0 49.2
III/ IV 30.0 50.8
Performance Status
0–2 52.0 88.2
3–4 7.0 11.8
International Prognostic Index
0 1.0 1.7
1 16.0 27.1
2 18.0 30.5
$ 3 24.0 40.7
Response
Complete 50.0 84.7
Refractory 6.0 10.1
Relapsed 7.0 11.0
Polymorphism
R (HR and RR) 44.0 74.6
HH 15.0 25.4
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agreement with the studies that were previously conducted
in primarily Caucasian DLBCL patients treated with R-
CHOP. One potential explanation for these results is that the
effects of FcR polymorphisms depend on the genetic
background of a given individual. However, it is also
possible that the anti-tumor activity of rituximab is
independent of this genetic factor and does not depend
upon immune effector mechanisms.15
In conclusion, we have shown that the H/R FccRIIa-131
polymorphism has no impact on treatment outcomes,
including the overall response rate, the overall survival
time and the disease-free survival time, in a Brazilian
population of DLBCL patients treated with R-CHOP.
Therefore, genetic mixture does not seem to affect the
influence of the FccRIIA-131 polymorphism on the treat-
ment responses of these patients.
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Figure 1- Effects of the H/R FccRIIA-131 polymorphism on 59 DLBCL patients treated with CHOP and rituximab. A. Overall survival,
calculated from the beginning of chemotherapy to either the date of death or the date of the last follow-up. B. Disease-free survival,
calculated from the beginning of the observed complete or partial treatment response until either the date of first recurrent disease
event (relapse, disease progression, treatment failure) or the date of the last follow-up.
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